Role of NFAT in Chronic Lymphocytic Leukemia and Other B-Cell Malignancies.
B-cell receptor
chronic lymphocytic leukemia
lymphoid malignancies
lymphoma
nuclear factor of activated T cells
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
08
01
2021
accepted:
15
03
2021
entrez:
19
4
2021
pubmed:
20
4
2021
medline:
20
4
2021
Statut:
epublish
Résumé
In recent years significant progress has been made in the clinical management of chronic lymphocytic leukemia (CLL) as well as other B-cell malignancies; targeting proximal B-cell receptor signaling molecules such as Bruton Tyrosine Kinase (BTK) and Phosphoinositide 3-kinase (PI3Kδ) has emerged as a successful treatment strategy. Unfortunately, a proportion of patients are still not cured with available therapeutic options, thus efforts devoted to studying and identifying new potential druggable targets are warranted. B-cell receptor stimulation triggers a complex cascade of signaling events that eventually drives the activation of downstream transcription factors including Nuclear Factor of Activated T cells (NFAT). In this review, we summarize the literature on the expression and function of NFAT family members in CLL where NFAT is not only overexpressed but also constitutively activated; NFAT controls B-cell anergy and targeting this molecule using specific inhibitors impacts on CLL cell viability. Next, we extend our analysis on other mature B-cell lymphomas where a distinct pattern of expression and activation of NFAT is reported. We discuss the therapeutic potential of strategies aimed at targeting NFAT in B-cell malignancies not overlooking the fact that NFAT may play additional roles regulating the inflammatory microenvironment.
Identifiants
pubmed: 33869054
doi: 10.3389/fonc.2021.651057
pmc: PMC8047411
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
651057Informations de copyright
Copyright © 2021 Sana, Mantione, Angelillo and Muzio.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Cancer. 2018 Jan 15;142(2):322-333
pubmed: 28921505
Am J Hematol. 2003 Sep;74(1):1-8
pubmed: 12949883
J Immunol. 1998 Jul 1;161(1):277-85
pubmed: 9647234
Curr Mol Med. 2013 May;13(4):543-54
pubmed: 22950383
Immunity. 1998 Jan;8(1):125-34
pubmed: 9462518
Nat Rev Cancer. 2016 Mar;16(3):145-62
pubmed: 26911189
Biochem Genet. 2021 Feb 5;:
pubmed: 33544297
Nat Med. 2018 Jun;24(6):868-880
pubmed: 29785028
Genes Dev. 2003 Sep 15;17(18):2205-32
pubmed: 12975316
Biochim Biophys Acta. 2014 Dec;1846(2):297-311
pubmed: 25072963
Clin Cancer Res. 2016 Apr 1;22(7):1547-9
pubmed: 26847060
Cancer J. 2019 Nov/Dec;25(6):428-435
pubmed: 31764124
Blood. 2020 Jan 9;135(2):121-132
pubmed: 31794606
Cardiovasc Drug Rev. 2007 Summer;25(2):175-87
pubmed: 17614939
Am J Pathol. 2008 Jan;172(1):215-24
pubmed: 18156209
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6955-60
pubmed: 12011454
Mol Cell Biol. 2004 May;24(10):4184-95
pubmed: 15121840
Nature. 1995 Jul 20;376(6537):263-7
pubmed: 7542362
J Immunol. 2011 Apr 15;186(8):4835-44
pubmed: 21398617
Leuk Lymphoma. 1996 Nov;23(5-6):583-92
pubmed: 9031090
Curr Opin Oncol. 2019 Nov;31(6):568-573
pubmed: 31593975
Br J Haematol. 2005 Feb;128(3):333-42
pubmed: 15667535
Epigenetics. 2012 Jun 1;7(6):567-78
pubmed: 22534504
Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13459-64
pubmed: 14595020
Cell Cycle. 2016 Sep;15(17):2346-59
pubmed: 27399331
Immunity. 1998 Jan;8(1):115-24
pubmed: 9462517
Nature. 1998 Mar 12;392(6672):182-6
pubmed: 9515963
Blood. 2020 Jan 9;135(2):81
pubmed: 31917839
N Engl J Med. 2019 Aug 1;381(5):432-443
pubmed: 31365801
Blood. 2013 May 9;121(19):3879-88, S1-8
pubmed: 23460614
Immunity. 1996 Apr;4(4):397-405
pubmed: 8612134
Eur J Immunol. 2012 Aug;42(8):1924-31
pubmed: 22706795
Science. 1997 Mar 28;275(5308):1930-4
pubmed: 9072970
Nat Rev Clin Oncol. 2019 Nov;16(11):684-701
pubmed: 31278397
J Exp Med. 2011 Apr 11;208(4):823-39
pubmed: 21464221
Haematologica. 2011 Mar;96(3):353-5
pubmed: 21357715
Int J Hematol. 2000 Jan;71(1):59-65
pubmed: 10729995
Lancet Oncol. 2019 Jan;20(1):43-56
pubmed: 30522969
Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10673-8
pubmed: 15247420
Nat Immunol. 2002 Jan;3(1):48-54
pubmed: 11740499
Nat Commun. 2017 Oct 2;8(1):755
pubmed: 28970470
Cell Calcium. 2007 Aug;42(2):145-56
pubmed: 17572487
J Leukoc Biol. 2019 Mar;105(3):531-538
pubmed: 30556925
Mol Cell. 2000 Sep;6(3):539-50
pubmed: 11030334
Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13520-5
pubmed: 18765795
Blood. 2002 May 15;99(10):3742-7
pubmed: 11986231
Nature. 2006 Jun 1;441(7093):646-50
pubmed: 16511445
J Immunol. 2006 Aug 1;177(3):1510-5
pubmed: 16849457
Cytometry B Clin Cytom. 2018 Jan;94(1):121-128
pubmed: 29024461
Immunity. 1998 Nov;9(5):627-35
pubmed: 9846484
Front Immunol. 2018 Nov 27;9:2747
pubmed: 30538703
Leuk Lymphoma. 1995 Dec;20(1-2):131-6
pubmed: 8750634
Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2538-42
pubmed: 10051678
Immunity. 2001 Jan;14(1):13-20
pubmed: 11163226
Eur J Immunol. 2003 Jan;33(1):1-11
pubmed: 12594826
Cell Cycle. 2008 Feb 1;7(3):297-303
pubmed: 18235236
J Immunol. 2005 Apr 15;174(8):4797-802
pubmed: 15814705
J Exp Med. 2012 Feb 13;209(2):379-93
pubmed: 22312110
Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16091-6
pubmed: 24043824
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Exp Mol Med. 2013 Jul 19;45:e32
pubmed: 23867654
Nat Genet. 2016 Mar;48(3):253-64
pubmed: 26780610
Blood. 2014 Mar 20;123(12):1772-4
pubmed: 24652958
Blood. 2010 Nov 11;116(19):3899-906
pubmed: 20664054
Haematologica. 2011 Mar;96(3):408-16
pubmed: 21134984
Cell Mol Immunol. 2019 May;16(5):508-520
pubmed: 29907883
Blood. 2008 Jul 1;112(1):188-95
pubmed: 18292287
Immunity. 2000 Mar;12(3):293-300
pubmed: 10755616
Science. 1999 Sep 24;285(5436):2129-33
pubmed: 10497131
J Immunol. 2010 Dec 1;185(11):6624-35
pubmed: 21037089
Biochim Biophys Acta. 2002 Oct 9;1588(1):41-7
pubmed: 12379312
Nature. 1998 Mar 12;392(6672):186-90
pubmed: 9515964
Pflugers Arch. 2002 Aug;444(5):579-85
pubmed: 12194010
Blood. 2018 Oct 25;132(17):1805-1817
pubmed: 30209121
Int Immunol. 1995 Mar;7(3):381-92
pubmed: 7540861
J Biol Chem. 2011 Apr 29;286(17):14795-803
pubmed: 21325277
Blood. 2012 Jul 12;120(2):356-65
pubmed: 22613791
Curr Oncol Rep. 2017 Sep;19(9):61
pubmed: 28755313
Haematologica. 2018 Dec;103(12):2069-2078
pubmed: 29976738
Front Oncol. 2020 Jun 25;10:894
pubmed: 32670873
Front Immunol. 2019 Feb 19;10:270
pubmed: 30873159
Cell Immunol. 2020 Mar;349:104048
pubmed: 32014271
Biochim Biophys Acta. 2016 Mar;1863(3):401-413
pubmed: 26193078
Blood. 2006 Jun 1;107(11):4540-8
pubmed: 16497967
Blood. 2005 Dec 1;106(12):3940-7
pubmed: 16099873
N Engl J Med. 2014 Jun 12;370(24):2286-94
pubmed: 24869598
Nat Rev Immunol. 2010 Sep;10(9):645-56
pubmed: 20725108
Science. 1996 May 10;272(5263):892-5
pubmed: 8629027
Oncotarget. 2016 Dec 6;7(49):80599-80611
pubmed: 27716624
Adv Exp Med Biol. 2014;816:315-33
pubmed: 24818728